Shionogi Inc., the U.S. subsidiary of Shionogi & Co. Ltd., announced June 2 that current President and CEO Akira Kato will leave the Florham Park division to lead the parent company in Japan.

With his departure, the pharmaceutical company introduced a reorganization of its U.S. executive team, effective July 1:

Promotions

• Nate McCutcheon, current chief operating officer, will be promoted to president and CEO;
• Tadashi Hara, current executive vice president and chief financial officer, will be named executive vice president and chief global operations officer—a new role for the company;
• Gianine Esposito will be promoted to senior vice president and chief human resources officer.

Hires

• Margaret Borys joined Shionogi Inc. as senior vice president and chief commercial officer;
• Masahiro Fujita come on board as senior vice president and chief financial officer.

The company added that Joseph Spagnardi will continue in his role as executive vice president, Legal and Compliance.

“As I return to Japan to lead Shionogi Pharma Co. Ltd, it was clear Nate McCutcheon was the right choice to take over the company’s helm given his professional experience and leadership abilities,” Kato said in a statement. “Both myself and the leadership in Japan have great confidence in his ability to advance Shionogi’s vision here in the U.S.”

While McCutcheon praised Kato – who has been with the company since 1990, according to his company profile – and also noted Shionogi’s successes — including the launch of Fetroja, a treatment for complicated urinary tract infections — he said the new team must “turn to the tremendous opportunities we have in the future in terms of both organic and inorganic growth opportunities.”

“As the new president and CEO of Shionogi’s U.S. group company, I have full confidence that with the right team and the support from headquarters in Japan we can develop, acquire and commercialize a portfolio of products to transform our U.S. business,” McCutcheon added.